Home   |  Publications   |   Conferences    |  Join   |   Contact   | Sitemap  

Current Synthetic and Systems Biology

Open Access
ISSN: 2332-0737
home » synthetic-and-systems-biology-achieving-impossible-missions-deciphering-human-complex-disease-genetics-2332-0737 Rss Feed Rss Feed
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals that operates with the help of 50,000 + Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Upcoming and Previous Symposiums and
Workshops on Pharma, Medicine, Science and Technology
Editorial Open Access
Synthetic and Systems Biology: Toward Achieving Impossible Missions and Deciphering Human Complex Disease Genetics
Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, Quebec H2L 4M1, Canada Yue Zhang*
Corresponding Author : Yue Zhang
Osteoarthritis Research Unit
University of Montreal Hospital Research Centre (CRCHUM)
Notre-Dame Hospital, Montreal
Quebec H2L 4M1, Canada
Tel: 1-514-890-8000 ext 23875
Fax: 1-514-412-7583
E-mail: zhanglee2006@gmail.com
Received November 09, 2013; Accepted November 12, 2013; Published November 15, 2013
Citation: Zhang Y (2013) Synthetic and Systems Biology: Toward Achieving Impossible Missions and Deciphering Human Complex Disease Genetics. Curr Synthetic Sys Biol 2:e102. doi: 10.4172/2332-0737.1000e102
Copyright: © 2013 Zhang Y. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google
Visit for more related articles at
DownloadCurrent Synthetic and Systems Biology
Many pioneering works have inspired researchers to stay up-todate on synthetic and system biology. Several cases that were originally thought to be exceptionally difficult, if not impossible, have been carried out successfully, such as Craig Venter’s creation of the world’s first synthetic life form. At a system level, nucleic reprogramming succeeded in frog half a century ago (reviewed in [1]); but doubts about whether or not this was impossible lingered until 40 years later, when a cocktail of four transcriptional factors systematically reprogrammed the somatic cells to stem cells [1-3]. Other cases include that telomerase reactivation may lead to the reversal of tissue degeneration in aged telomerase-deficient mice [4] and muscle-derived stem/progenitor cell dysfunction acts as a healthspan and lifespan limiting factor for murine progeria reversal [5].
Here, we focus on the latest impossible or exceptionally difficult missions, plus those of the future, i.e. decoding the complex diseases genetics and their possible modified nutritional, tour and other benign environmental treatments, which most of us could easily have and best exercise. Some complex diseases currently considered “difficult – to be addressed” are largely diseases of aging. For instance, starting for relatively simple neurodegenerative disorders like Parkinson’s disease (PD) , today, no drugs exist to address the underlying pathology; for autoimmune diseases (ADs), no one is even sure what causes such outcomes; and for cancer, though billions of dollars have been invested and millions of articles published, there is still a long way to go to deal with them both theoretically and therapeutically to satisfy researchers and sufficiently match the expectations of patients. Successful creation of disease models and screening of targets are expected to be identified for such diseases and thus help slow or even prevent disease progression.
Latest Achieved Impossible Mission
Genetically engineered yeast cells with forced expression of alphasynuclein has recently been is established as a robust model for the toxicity of this protein, which underlies PD but is lacking in yeast in nature [6,7]. Similarly, a Caenorhabditis elegans worm model has been successfully created for PD [2].
Though efficient, a target-based screening approach for some agingrelated diseases has a serious limitation that it essentially takes place in a test tube, which is far from a real tissue, organ or organism, and hardly reveals or replicates the process of aging and development (i.e. the three physical dimensions and the time dimension are incomplete in those studies) so that some scrutinized drugs may behave differently when they are moved from the in vitro environment into a living organism. However, some “ proteins believed to be “undruggable were promisingly targeted [7] and “impossible” disease modelling (e.g. for PD) has been achieved along with a living organism system-level platform [6,7].
However, if most human complex diseases are the consequence of the ensemble effects of polygenic variation at many loci, then both their functional relationships and their identities are keys to understanding the disease physiology. Systems Biology has the ability to analyse such widespread genetic variation and elucidate ultimately the cause- effects of disease mechanisms. This may spur new thinking if the current chasm between correlations of genome loci and causality is stemming in part from a limiting theoretical framework currently -derived from Mendelian genetics [8]. Of certain, experimental evidence is required from cells, tissues, or the rare patient, to clarify the role of a specific gene in a disease via a synthesis of multiple biological disciplines with emphasis here on the role of genetic variations identified in genome wide associated studies (GWAS) that are likely intrinsic to the biological process and solid confirmation of tractable experimental models.
Accomplishing Mission Impossible: the example of protection from ADs and associated cancers via the genetic regulatory network of the vitamin D receptor (VDR) and vitamin D
Importantly, VDR mediate the majority of cellular responses to vitamin D and environment insults that have potential in synthetic biology. The responsiveness of VDR to ligands and stimuli make them ideal sensory receptor modules of synthetic gene networks.
Immunologists were awarded the 2011 Nobel Prize in Pathology and Medicine, but autoimmunity remains largely unclear, if not mysterious. For one century, controversy and uncertainty has persisted on the beneficial effects of vitamin D supplementation against ADs and/or cancers [9-13]. Morever, we predict, without a thorough understanding of the underlying mechanisms, it is insufficient to solely rely on a semi-“shotgun” strategy for clinical trials. The gaps will make this topic backward without aging and development data. Based on genome-wide target genes screened with different model organisms at different stages, the genetic regulatory network (GRN) revealed that heterochronic gene DAF-12/VDR acts as a potential common basis preventing some ADs and associated cancers, and may help resolve such controversies [14] as follows: the explicit molecular mechanism of the VDR in response to the environment will first need go along with different polygeneic gene sets. As a capacitator, DAF-12/VDR may buffer genetic mutations and/or variations. Environmental factorinduced malfunctional DAF-12/VDR may lead to local dys-regulation of the expression of an array of its target genes [14] (Table 1 I,II), followed by their citrullination, mediated by its orchestrated autophagy process, and consequently end with autoimmunity (Table 1 III). In fact, there are abundant and ubiquitous natural IgG auto-antibodies in human sera, and their quantity is influenced by age, gender and disease [15]. In nature, the reversal of a diseased status with vitamin D supplementation is more difficult and/or complex than the breakdown of robust health. Lastly, after long-term selection for some populations, some diseases might be even independent of the malfunction of DAF- 12/VDR. But would these findings apply in human cells? To answer that question, other research will be needed.
However, Miller FW et al. [16], reporting on genome-wide association study (GWAS) of dermatomyositis (DM), revealed a genetic overlap with other ADs, the first identification of genetic predispositions towards ADs shared with DM. Moreover, the patterns of genetic overlap across ADs have emerged [11,16] . Further, our recent ChIP-chip screening for DAF-12/VDR target genes [17,18], along with NCBI Aceview, may reveal many translatable targets overlapping with validated homologues identified in human VDR studies that are significantly enriched near genes that are pathologically associated with ADs [2,19], including phospholipase C-like 1 (PLCL1), B lymphoid tyrosine kinase (BLK), i.e. pll-1 and src-1 respectively. Further, one new study reported that integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma. The key regulator FBN1 for scleroderma is the homologue of fbl-1 in Caenorhabditis elegans [20]. Another GWAS identified a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis (RA) [21]. Interestingly, sperm-associated antigen 16 (SPAG16), matrix metallopeptidase 1 and 3 (MMP1 and MMP3) are VDR [17,22-24] target genes too, i.e. wdr-5.1 (C14B1.4) and H36L18.1 respectively (but there is a single congruent C. elegans homologue for human MMP1 and MMP3) . This is the first time for a VDR target gene variant that has the significance of being a “beneficial” locus, i.e. uniquely, SPAG16 influences MMP-3 activity and protects against joint destruction in autoantibody-positive RA. Further, it is known that Wdr-5.1 is a component of the conserved H3K4 trimethylation (H3K4me3) complex and negatively regulates lifespan in C. elegans [24]; interestingly, WDR-5.1 activity also antagonizes SynMuv transcriptional repressors, which antagonize worm RAS signalling [25]. Vitamin D3 regulates matrix metallopeptidase (MMPI 3) in cultured human cells [26]. A malfunction in VDR could thus affect the pathogenesis of RA and possibly associated cancers [2,14]. Particularly, RA therapy now remains a challenge with the failure of anti-TNF therapy alone [27], but better inhibition of human Th17- mediated synovial inflammation has been shown with 1,25(OH)2D3 − an active vitamin D metabolite [28]. Importantly, MMP3 contributes to this process [17,28,29]. The highly-conserved targets of DAF-12/ VDR (e.g. MMP3/MMP1) [17] have synergic functions with its other evolutionarily “novel” targets (e.g. Interleukin-6) [29,30]. Strikingly, one GWAS previously reported that one allelic VDR variant may link to clinical autoimmune antibodies including the anti-p150 (TIF-1γ)/ p140 (TIF-1α ) [30] and TIF-1γ/α genes’ C. elegans homologues, flt-1 and nhl-2, are also direct targets of DAF-12/VDR (Table 1, III) [17]. In addition, the human homologues of other DAF-12/VDR targets genes such as let-418 /Mi-2β (best homologous to human AIRE) are associated with DM (Table 1 ,III) [17,31]. Since DAF-12/VDR may buffer internal or external challenges in C. elegans [17], its functional counterpart human VDR may possibly prevent the breakdown of robust normal human health [16,32]. This is similar to DAF-12’s synergy with its target genes in the mutation phenotype. Although a weak (or no) mutation phenotype appears with particular VDR target genes but there is still a genetic tendency to develop a disease in patients under the right conditions, an outside invader like a virus or environmental factor, e.g. vitamin D deficiency or a lack of UVB, might trigger ADs. Interestingly, Liu F et al. [33] showed that DAF-12/VDR plays a critical role in the innate immune response. In mammalian systems, VDR may have a more complex adaptive immune response than its conserved innate immune response [28,34]. A combination of factors including a genetic regulatory network and those from VDR and its target genes is probably at work for ADs.
However, further detailed investigation will need focus on other adult stages and embryonic stages for DAF-12/VDR will give a comprehensive view on genetic regulatory networks. Since human patients are outbreed and experimentally–intractable; cell culture and organelle has its innate limitations, but one of two developmental stages can easily cover the equivalent time span such as twenty years for some trials and be subject to genetic manipulation. Particularly, the C. elegans community had built a genome-wide RNA interference library to knock down any gene. We can systematically look at genetic interactions, and streamline -like in a factory for disruption of genes in pathways or in redundancy can be set up [35,36]. If using the mouse model, we may profit one-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering to disrupt multiple loci [37]. Lastly, because VDR are important pharmacological targets of such human diseases, genes encoding their protein/peptide ligands can also be incorporated as target genes of the response output elements of synthetic gene networks. Unlike some abovementioned mission, this is thus one possible mission for VDR to construct therapeutic synthetic gene networks. Besides, if this may be proven, excellent chance to elucidate that particularly their loci are also identifying as disease-causing target genes as well, consequently, they are not a list of unbiased candidates insufficient for implicating specific gene(s) in a disease, but promote the role of its target genes as being “causal,” rather than just “associated,” in a disease process, and VDR may be fit for latest modified Koch’s postulates for complex human diseases and traits [8].
How about equipping the worm with an adaptive immune system? Right now, this is one seemingly impossible mission. If, indeed, it could work, then it will shed light not only AD prevention /cure but also on cancer immunotherapy. The next step will simply be using model organism genetics to identify a compound and its mechanism of action against the fundamental pathology of these diseases, a process which may benefit from the power of multiple organisms (particularly including living organism systems) [6,7]. We may eventually accomplish some new impossible missions in the future.



 Download    pdf version of this article


Tables at a glance

Table 1
Select your language of interest to view the total content in your interested language
Share This Article
About Journal
Disc Journal Home
Disc Editorial Board Members
Disc Current Issue
Disc Previous Issue
Disc Instructions for Authors
Disc Submit Manuscript
Disc Contact Editorial Office
Related Journals
Disc Proteomics Journal
Disc Journal of Biotechnology
Disc Biomaterial Journals
Disc Computational Science Journal
Disc Systems Biology Journal
Related Conferences


Systems Biology Conference


Aug 22-23, 2016, Philadelphia, USA


Synthetic Biology Conference
Aug 18-19, 2016, London, UK


Integrative Biology Conference
June 13-15, 2016 Berlin, Germany

10th Asia Pacific

Bio Congress
July 25-27, 2016 Bangkok, Thailand
Disc 4thInternational Conference and Exhibition on Metabolomics & Systems Biology
April 27-29, 2015 Philadelphia, USA
Disc Global summit and Expo on Multimedia & Applications
August 10-11, 2015 at Birmingham, UK
Disc World Congress and Expo on Medical Devices
September 21-23, 2015 in Seattle, USA
Disc International Conference on Synthetic Biology
September 28-30, 2015, Houston, USA
Article Tools
Disc Export citation
Disc Share/Blog this article
Disc Recommend to your Librarian
Article usage
  Total views: 7886
  [From(publication date):
March-2014 - Sep 03, 2015]
  Breakdown by view type
  HTML page views : 7107
  PDF downloads :779
Subject wise
Open Access Journals
Disc Clinical Journals
Disc Chemistry Journals
Disc Engineering Journals
Disc Environmental Journals
Disc Life Sciences Journals
  Read More »

Post your comment

Your question:
Anti Spam Code:
  Reload  Can't read the image? click here to refresh

OMICS International Conferences 2015-16

Meet Inspiring Speakers and Experts at our 1000+ Global Annual Meetings
Conferences By Country
  USA   Spain   Poland
  Australia   Canada   Austria
  UAE   Switzerland   Turkey
  Italy   France   Finland
  Germany   India   Ukraine
  UK   Malaysia   Denmark
  Japan   Singapore   Mexico
  Brazil   South Africa   Norway
  South Korea   New Zealand   China
  Netherlands   Philippines
Medical & Clinical Conferences
Microbiology Oncology & Cancer
Diabetes & Endocrinology Cardiology
Nursing Dentistry
Healthcare Management Physical Therapy Rehabilitation
Neuroscience Psychiatry
Immunology Infectious Diseases
Gastroenterology Medical Ethics & Health Policies
Genetics & Molecular Biology Palliativecare
Pathology Reproductive Medicine & Women Healthcare
Alternative Healthcare Surgery
Pediatrics Radiology
Conferences by Subject
Pharmaceutical Sciences
Pharma Marketing & Industry
Environmental Science
Physics & Materials Science
EEE & Engineering
Chemical Engineering
Business Management
Geology & Earth science
©2008-2015 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version